FDA Approves First Long-Acting Antibody Shot to Prevent RSV in Infants and Toddlers

The FDA approved AstraZeneca and Sanofi's Beyfortus, the first long-acting antibody shot to prevent RSV in infants and toddlers.
Beyfortus is a monoclonal antibody given as a single injection before RSV season and provides protection for up to 5 months.
In clinical trials, Beyfortus reduced the risk of RSV infections requiring medical care by up to 75% and hospitalizations by up to 78%.
RSV is the leading cause of hospitalization in infants under one year old, with around 80,000 children hospitalized annually.
Beyfortus is the first RSV preventive approved for all infants regardless of health status, unlike the previous monthly injection.